{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:51:16Z","timestamp":1790380276048,"version":"4.1.0"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteoanabolic agents are used as a first line treatment in patients at high fracture risk. The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone mineral density (BMD), and bone strength by activating PTH receptors on osteoblasts. Romosozumab (ROMO), a humanized monoclonal antibody against sclerostin, dramatically but transiently stimulates bone formation and persistently reduces bone resorption. Osteoanabolic agents increase BMD and bone strength while being more effective than antiresorptives in reducing fracture risk in postmenopausal women. However, direct comparisons of the antifracture benefits of osteoanabolic therapies are limited. In a direct comparison of TPTD and ABL, the latter resulted in greater BMD increases at the hip. While no differences in vertebral or non-vertebral fracture risk were observed between the two drugs, ABL led to a greater reduction of major osteoporotic fractures. Adverse event profiles were similar between the two agents except for hypercalcemia, which occurred more often with TPTD. No direct comparisons of fracture risk reduction between ROMO and the PTH1R agonists exist. Individual studies have shown greater increases in BMD and bone strength with ROMO compared with TPTD in treatment-naive women and in women previously treated with bisphosphonates. Some safety aspects, such as a history of tumor precluding the use of PTH1R agonists, and a history of major cardiovascular events precluding the use of ROMO, should also be considered when choosing between these agents. Finally, convenience of administration, reimbursement by national health systems and length of clinical experience may influence patient choice.<\/jats:p>","DOI":"10.1093\/ejendo\/lvae076","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:20:31Z","timestamp":1719555631000},"page":"R9-R21","source":"Crossref","is-referenced-by-count":16,"title":["Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D","family":"Anastasilakis","sequence":"first","affiliation":[{"name":"Department of Endocrinology, 424 Military General Hospital , Thessaloniki 564 29 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P","family":"Yavropoulou","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, 1st Department of Propaedeutic and Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laikon University Hospital of Athens , Athens 115 27 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , Rome 00128 , Italy"},{"name":"Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome , Rome 00128 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"Department of Medical Research, 251 Hellenic Air Force & VA General Hospital , Athens 115 25 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-8623","authenticated-orcid":false,"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHU Lille , Lille 59000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , Rome 00128 , Italy"},{"name":"Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome , Rome 00128 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-3381","authenticated-orcid":false,"given":"Anda Mihaela","family":"Naciu","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , Rome 00128 , Italy"},{"name":"Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome , Rome 00128 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1906","authenticated-orcid":false,"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Technische Universit\u00e4t Dresden , Dresden 01307 , Germany"},{"name":"Center for Healthy Aging, Technische Universit\u00e4t Dresden , Dresden 01307 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"issue":"6","key":"2024073119301069900_lvae076-B1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024073119301069900_lvae076-B2","doi-asserted-by":"crossref","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"3","key":"2024073119301069900_lvae076-B3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024073119301069900_lvae076-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024073119301069900_lvae076-B5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"1","key":"2024073119301069900_lvae076-B6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"17","key":"2024073119301069900_lvae076-B7","doi-asserted-by":"crossref","first-page":"e90874","DOI":"10.1172\/jci.insight.90874","article-title":"Prevention of breast cancer skeletal metastases with parathyroid hormone","volume":"2","author":"Swami","year":"2017","journal-title":"JCI Insight"},{"issue":"5","key":"2024073119301069900_lvae076-B8","first-page":"e1300","article-title":"Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis","volume":"9","author":"Tella","year":"2017","journal-title":"Cureus"},{"key":"2024073119301069900_lvae076-B9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/DDDT.S127568","article-title":"Profile of romosozumab and its potential in the management of osteoporosis","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2024073119301069900_lvae076-B10","doi-asserted-by":"crossref","DOI":"10.1007\/s42000-023-00521-y","article-title":"Tauhe story of sclerostin inhibition: the past, the present, and the future","author":"Anastasilakis","year":"2024","journal-title":"Hormones (Athens)"},{"issue":"2","key":"2024073119301069900_lvae076-B11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bone.2012.09.017","article-title":"For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases","volume":"54","author":"Manolagas","year":"2013","journal-title":"Bone"},{"issue":"13","key":"2024073119301069900_lvae076-B12","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"1","key":"2024073119301069900_lvae076-B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1359\/jbmr.061002","article-title":"Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation","volume":"22","author":"van Bezooijen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024073119301069900_lvae076-B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","article-title":"Sclerostin's role in bone's adaptive response to mechanical loading","volume":"96","author":"Galea","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024073119301069900_lvae076-B15","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1210\/jc.2013-3249","article-title":"Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women","volume":"99","author":"Fujita","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024073119301069900_lvae076-B16","doi-asserted-by":"crossref","first-page":"bvac027","DOI":"10.1210\/jendso\/bvac027","article-title":"Parathyroid hormone regulates circulating levels of sclerostin and FGF23 in a primary hyperparathyroidism model","volume":"6","author":"Nagata","year":"2022","journal-title":"J Endocr Soc"},{"issue":"5","key":"2024073119301069900_lvae076-B17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024073119301069900_lvae076-B18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI40568","article-title":"Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice","volume":"120","author":"Walker","year":"2010","journal-title":"J Clin Invest"},{"issue":"4","key":"2024073119301069900_lvae076-B19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.14310\/horm.2002.1111024","article-title":"The role of the Wnt signaling pathway in osteoblast commitment and differentiation","volume":"6","author":"Yavropoulou","year":"2007","journal-title":"Hormones (Athens)"},{"issue":"39","key":"2024073119301069900_lvae076-B20","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1074\/jbc.M500608200","article-title":"Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression","volume":"280","author":"Gaur","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"2024073119301069900_lvae076-B21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2443.2008.01258.x","article-title":"Bone morphogenetic protein-2 enhances Wnt\/beta-catenin signaling-induced osteoprotegerin expression","volume":"14","author":"Sato","year":"2009","journal-title":"Genes Cells"},{"issue":"50","key":"2024073119301069900_lvae076-B22","doi-asserted-by":"crossref","first-page":"41155","DOI":"10.1074\/jbc.M506366200","article-title":"Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-\u03baB ligand","volume":"280","author":"Schneeweis","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"2024073119301069900_lvae076-B23","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/jc.2015-3698","article-title":"Effect of teriparatide on bone formation in the human femoral neck","volume":"101","author":"Cosman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"32","key":"2024073119301069900_lvae076-B24","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1074\/jbc.R600015200","article-title":"Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors","volume":"281","author":"Gordon","year":"2006","journal-title":"J Biol Chem"},{"issue":"10","key":"2024073119301069900_lvae076-B25","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"2024073119301069900_lvae076-B26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-015-0417-7","article-title":"Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis","volume":"75","author":"Appelman-Dijkstra","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"2024073119301069900_lvae076-B27","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"19","key":"2024073119301069900_lvae076-B28","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"2024073119301069900_lvae076-B29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1507\/endocrj.K07E-123","article-title":"Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis","volume":"55","author":"Anastasilakis","year":"2008","journal-title":"Endocr J"},{"issue":"2","key":"2024073119301069900_lvae076-B30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024073119301069900_lvae076-B31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"2024073119301069900_lvae076-B32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024073119301069900_lvae076-B33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024073119301069900_lvae076-B34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"issue":"15","key":"2024073119301069900_lvae076-B35","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"2024073119301069900_lvae076-B36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024073119301069900_lvae076-B37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jbmr.3309","article-title":"Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024073119301069900_lvae076-B38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.3350","article-title":"Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study","volume":"33","author":"Dempster","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024073119301069900_lvae076-B39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024073119301069900_lvae076-B40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jbmr.4243","article-title":"Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis","volume":"36","author":"Dempster","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024073119301069900_lvae076-B41","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-Forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024073119301069900_lvae076-B42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-Based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024073119301069900_lvae076-B43","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jbmr.2825","article-title":"Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024073119301069900_lvae076-B44","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"key":"2024073119301069900_lvae076-B45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"van Lierop","year":"2017","journal-title":"Bone"},{"issue":"2","key":"2024073119301069900_lvae076-B46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"6","key":"2024073119301069900_lvae076-B47","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2024073119301069900_lvae076-B48","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.25011\/cim.v40i3.28394","article-title":"Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin Invest Med"},{"issue":"9886","key":"2024073119301069900_lvae076-B49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"17","key":"2024073119301069900_lvae076-B50","first-page":"8253","article-title":"Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials","volume":"27","author":"Wang","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"2024073119301069900_lvae076-B51","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024073119301069900_lvae076-B52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13018-023-03595-x","article-title":"Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis","volume":"18","author":"Hong","year":"2023","journal-title":"J Orthop Surg Res"},{"issue":"6","key":"2024073119301069900_lvae076-B53","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00198-019-04890-2","article-title":"Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis","volume":"30","author":"Watts","year":"2019","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024073119301069900_lvae076-B54","first-page":"2640","article-title":"Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis","volume":"23","author":"Yang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"9","key":"2024073119301069900_lvae076-B55","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clin Exp Res"},{"issue":"16","key":"2024073119301069900_lvae076-B56","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2024073119301069900_lvae076-B57","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2024073119301069900_lvae076-B58","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10102","key":"2024073119301069900_lvae076-B59","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"2024073119301069900_lvae076-B60","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"2024073119301069900_lvae076-B61","doi-asserted-by":"crossref","first-page":"1188969","DOI":"10.3389\/fendo.2023.1188969","article-title":"Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2024073119301069900_lvae076-B62","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024073119301069900_lvae076-B63","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"4","key":"2024073119301069900_lvae076-B64","doi-asserted-by":"crossref","first-page":"ziae016","DOI":"10.1093\/jbmrpl\/ziae016","article-title":"Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study","volume":"8","author":"Adami","year":"2024","journal-title":"JBMR Plus"},{"issue":"10117","key":"2024073119301069900_lvae076-B65","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"2024073119301069900_lvae076-B66","doi-asserted-by":"crossref","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"},{"issue":"20","key":"2024073119301069900_lvae076-B67","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"2024073119301069900_lvae076-B68","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"13","key":"2024073119301069900_lvae076-B69","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2024073119301069900_lvae076-B70","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"issue":"12","key":"2024073119301069900_lvae076-B71","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024073119301069900_lvae076-B72","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024073119301069900_lvae076-B73","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","article-title":"Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024073119301069900_lvae076-B74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11657-019-0672-4","article-title":"No impact of anti-rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis","volume":"15","author":"Ferrieres","year":"2020","journal-title":"Arch Osteoporos"},{"key":"2024073119301069900_lvae076-B75","doi-asserted-by":"crossref","first-page":"116610","DOI":"10.1016\/j.bone.2022.116610","article-title":"Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis","volume":"167","author":"Seeto","year":"2023","journal-title":"Bone"},{"key":"2024073119301069900_lvae076-B76","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"issue":"13","key":"2024073119301069900_lvae076-B77","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.3390\/ijms21134779","article-title":"Sclerostin and vascular pathophysiology","volume":"21","author":"Catalano","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2024073119301069900_lvae076-B78","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1161\/ATVBAHA.122.317635","article-title":"Role of sclerostin in cardiovascular disease","volume":"42","author":"Golledge","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2024073119301069900_lvae076-B79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.1803","article-title":"Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus","volume":"28","author":"Hamann","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024073119301069900_lvae076-B80","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","article-title":"Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Ominsky","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2024073119301069900_lvae076-B81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","article-title":"Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study","volume":"81","author":"Chouinard","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"issue":"10","key":"2024073119301069900_lvae076-B82","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/art.42538","article-title":"Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization","volume":"75","author":"Zheng","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2024073119301069900_lvae076-B83","author":"Evenity\u00ae (Romosozumab)"},{"issue":"5","key":"2024073119301069900_lvae076-B84","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/jcm10050996","article-title":"The impact of antiosteoporotic drugs on glucose metabolism and fracture risk in diabetes: good or bad news?","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"2024073119301069900_lvae076-B85","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/cen.13139","article-title":"Effect of teriparatide treatment on endothelial function, glucose metabolism and inflammation markers in patients with postmenopausal osteoporosis","volume":"85","author":"Celer","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2024073119301069900_lvae076-B86","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-2008-1078729","article-title":"Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Horm Metab Res"},{"issue":"4","key":"2024073119301069900_lvae076-B87","doi-asserted-by":"crossref","first-page":"e10346","DOI":"10.1002\/jbm4.10346","article-title":"Abaloparatide in postmenopausal women with osteoporosis and type 2 diabetes: a post hoc analysis of the ACTIVE study","volume":"4","author":"Dhaliwal","year":"2020","journal-title":"JBMR Plus"},{"key":"2024073119301069900_lvae076-B88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bone.2014.07.008","article-title":"Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs","volume":"67","author":"Mazziotti","year":"2014","journal-title":"Bone"},{"issue":"1","key":"2024073119301069900_lvae076-B89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024073119301069900_lvae076-B90","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2024073119301069900_lvae076-B91","author":"Forsteo\u00ae (Teriparatide)"},{"key":"2024073119301069900_lvae076-B92","author":"Eladynos\u00ae (Abaloparatide)"},{"issue":"8","key":"2024073119301069900_lvae076-B93","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024073119301069900_lvae076-B94","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jbmr.4695","article-title":"Romosozumab use and cardiovascular events","volume":"38","author":"Fusaro","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024073119301069900_lvae076-B95","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jbmr.4724","article-title":"Cardiovascular safety of romosozumab: new insights from postmenopausal women with chronic kidney disease","volume":"38","author":"Adami","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024073119301069900_lvae076-B96","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcph.2050","article-title":"Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab","volume":"62","author":"Hsu","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2024073119301069900_lvae076-B97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0024-3205(91)90402-W","article-title":"Digitalis sensitivity of Na+,K(+)-ATPase, myocytes and the heart","volume":"48","author":"Akera","year":"1991","journal-title":"Life Sci"},{"issue":"1","key":"2024073119301069900_lvae076-B98","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"issue":"9999","key":"2024073119301069900_lvae076-B99","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2024073119301069900_lvae076-B100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s42000-023-00491-1","article-title":"Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management","volume":"22","author":"Anastasilaki","year":"2023","journal-title":"Hormones (Athens)"},{"key":"2024073119301069900_lvae076-B101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","article-title":"Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies","volume":"116","author":"Langdahl","year":"2018","journal-title":"Bone"},{"issue":"10","key":"2024073119301069900_lvae076-B102","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1210\/jc.2018-02084","article-title":"Obesity, bariatric surgery, and fractures","volume":"104","author":"Lespessailles","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024073119301069900_lvae076-B103","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024073119301069900_lvae076-B104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024073119301069900_lvae076-B105","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"van de Laarschot","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024073119301069900_lvae076-B106"},{"key":"2024073119301069900_lvae076-B107"},{"issue":"2","key":"2024073119301069900_lvae076-B108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024073119301069900_lvae076-B109","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","article-title":"Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling","volume":"32","author":"Winzenrieth","year":"2021","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024073119301069900_lvae076-B110","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024073119301069900_lvae076-B111","doi-asserted-by":"crossref","first-page":"174409","DOI":"10.1016\/j.ejphar.2021.174409","article-title":"Abaloparatide: a review of preclinical and clinical studies","volume":"909","author":"Brent","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2024073119301069900_lvae076-B112","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-020-05718-0","article-title":"Long-term cancer surveillance: results from the Forteo patient registry surveillance study","volume":"32","author":"Gilsenan","year":"2021","journal-title":"Osteoporos Int"},{"issue":"10","key":"2024073119301069900_lvae076-B113","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5435\/JAAOS-D-22-01094","article-title":"Treatment of osteoporosis with anabolic agents and the risk of primary bone cancers: a study of 44,728 patients treated with teriparatide and abaloparatide","volume":"31","author":"McDonald","year":"2023","journal-title":"J Am Acad Orthop Surg"},{"issue":"9","key":"2024073119301069900_lvae076-B114","doi-asserted-by":"crossref","first-page":"e10665","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"issue":"12","key":"2024073119301069900_lvae076-B115","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2024073119301069900_lvae076-B116","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17474086.2017.1283213","article-title":"Emerging treatment approaches for myeloma-related bone disease","volume":"10","author":"Gavriatopoulou","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2024073119301069900_lvae076-B117","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11914-021-00663-1","article-title":"Anabolic agents for postmenopausal osteoporosis: how do you choose?","volume":"19","author":"Cosman","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"2024073119301069900_lvae076-B118","doi-asserted-by":"crossref","first-page":"116618","DOI":"10.1016\/j.bone.2022.116618","article-title":"Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis","volume":"167","author":"Ganapathy","year":"2023","journal-title":"Bone"},{"issue":"6","key":"2024073119301069900_lvae076-B119","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.081250","article-title":"Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate","volume":"24","author":"Cosman","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024073119301069900_lvae076-B120","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"McClung","year":"2020","journal-title":"Osteoporos Int"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae076\/58354509\/lvae076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/1\/R9\/58674220\/lvae076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/1\/R9\/58674220\/lvae076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:40:51Z","timestamp":1722480051000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/191\/1\/R9\/7700820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae076","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,28]]}}}